Body weight, appetite, glucose control, and energy expenditure. It is not FDA approved as of this guide’s publication.

Appetite, glycemic control, and body weight. Approval depends on the specific product and indication.

Glycemic control and chronic weight management under specific approved labels.

Much of the published evidence is preclinical. Online popularity should not be confused with proven human safety or efficacy.

Human therapeutic evidence is limited, and products sold as TB-500 are not FDA-approved medicines.

Metabolic homeostasis, mitochondrial communication, exercise response, and aging biology.

Forzinity received accelerated U.S. approval in 2025 to improve muscle strength in people with Barth syndrome weighing at least 30 kg. This does not approve research SS-31 vials or general energy and anti-aging uses.

Its approval is indication-specific. Medical screening and monitoring matter because GH/IGF-1 signaling has meaningful risks.

GH release and endocrine signaling. Marketing claims often run ahead of clinical evidence.

Regulatory status and evidence differ by country. It is not an FDA-approved medicine in the United States.

Claims about cognition and recovery should be separated from the quality and scale of supporting human evidence.

Extracellular matrix remodeling, collagen-related pathways, and topical cosmetic applications.

Confirm each ingredient and amount. A 70 mg total does not tell you how much of each compound is present. Claims for individual ingredients do not establish the blend’s benefits.

The supplied reference does not confirm the formula. Do not infer ingredients, gut benefits, safety, or equivalence from the name or an 80 mg total.

These are two different compounds. The exact CJC form and ingredient ratio matter; a combined vial total is not an ingredient breakdown. FDA identifies safety concerns for both.

Prescription uses depend on the product and diagnosis. General anti-aging, physique, and workout claims should not be treated as approved indications. GH replacement differs from stimulating GH release.

The reference describes body-composition and energy claims. These are not established human benefits, and the guide does not endorse it as a weight-loss treatment.

Its role inside cells does not prove that injections improve energy, cognition, recovery, or lifespan. Route, formulation, and clinical evidence must be evaluated separately.

Do not equate a vial marketed as Melanotan I with an approved afamelanotide implant. A shared compound name does not establish equivalent formulation, quality, or authorized use.

FDA notes reports of serious adverse events. It should not be presented as a safe tanning product.

Claims of longer life or dependable sleep improvement are not established clinical outcomes. FDA describes inadequate safety information.

A bottle size in mL is volume, not the amount of each nutrient. The ingredient list and concentrations are needed to understand the formulation. Do not assume a blend produces fat loss.

A fragment is not equivalent to full growth hormone. FDA notes limited safety information; marketing descriptions do not establish effective weight-loss treatment.

Gut and skin claims should be distinguished from demonstrated patient outcomes. Human safety evidence is insufficient.

Specific clinical research should not be generalized into a promise of stronger immunity. Regulatory status varies by country and product.

Bremelanotide’s approved product has a defined patient population and indication. This does not validate generic libido, fertility, or performance claims, or unregulated PT-141 vials.

Hormone signaling is not proof of improved fertility or sexual function. FDA identifies insufficient safety information.

Its name does not demonstrate an effective insomnia treatment or predictable sleep improvement. FDA notes missing safety information for proposed administration routes.

Read the individual BPC-157 and TB-500 entries above. Combining them does not establish faster healing, clinical effectiveness, or safety; the ingredient ratio also matters.

FDA-approved HCG products require a prescription. HCG is not approved for weight loss.

The reference’s cognitive-wellness positioning should not be read as proof of improved memory, prevention of brain aging, or a treatment for neurological disease.